ATE44238T1 - Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben. - Google Patents

Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.

Info

Publication number
ATE44238T1
ATE44238T1 AT84102119T AT84102119T ATE44238T1 AT E44238 T1 ATE44238 T1 AT E44238T1 AT 84102119 T AT84102119 T AT 84102119T AT 84102119 T AT84102119 T AT 84102119T AT E44238 T1 ATE44238 T1 AT E44238T1
Authority
AT
Austria
Prior art keywords
detoxified
gram
polysaccharide
negative bacterium
vaccine
Prior art date
Application number
AT84102119T
Other languages
German (de)
English (en)
Inventor
Grace C Tsay
Michael S Collins
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of ATE44238T1 publication Critical patent/ATE44238T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/802—Antibody or antigen-binding fragment thereof that binds gram-positive bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT84102119T 1983-03-14 1984-02-29 Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben. ATE44238T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/475,415 US4663160A (en) 1983-03-14 1983-03-14 Vaccines for gram-negative bacteria
EP84102119A EP0118831B1 (en) 1983-03-14 1984-02-29 Vaccines for gram-negative bacteria and method for the preparation thereof

Publications (1)

Publication Number Publication Date
ATE44238T1 true ATE44238T1 (de) 1989-07-15

Family

ID=23887470

Family Applications (1)

Application Number Title Priority Date Filing Date
AT84102119T ATE44238T1 (de) 1983-03-14 1984-02-29 Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.

Country Status (5)

Country Link
US (1) US4663160A (enExample)
EP (2) EP0118831B1 (enExample)
JP (1) JPS59175440A (enExample)
AT (1) ATE44238T1 (enExample)
DE (1) DE3478789D1 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
ATE77243T1 (de) * 1985-03-11 1992-07-15 Teijin Ltd E87ag-antigen des pseudomonas aeruginosa, monoklonale antikoerper dagegen und hybridom.
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
US4789544A (en) * 1986-05-23 1988-12-06 Midcon Labs. Inc. Co-vaccination using non-O-carbohydrate side-chain gram-negative bacteria preparation
US5043158A (en) * 1987-08-21 1991-08-27 Chembiomed, Ltd. Immunogenic compositions containing ordered carriers
DE3727987A1 (de) * 1987-08-21 1989-03-02 Sleytr Uwe B Pharmazeutische struktur
US5063054A (en) * 1988-04-18 1991-11-05 Joseph Chang Microbial products used for treatment of hepatitis
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
AU678549B2 (en) * 1992-01-16 1997-06-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Detoxified LPS-cholera toxin conjugate vaccine for prevention of cholera
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US6693517B2 (en) 2000-04-21 2004-02-17 Donnelly Corporation Vehicle mirror assembly communicating wirelessly with vehicle accessories and occupants
US6329925B1 (en) 1999-11-24 2001-12-11 Donnelly Corporation Rearview mirror assembly with added feature modular display
US6477464B2 (en) 2000-03-09 2002-11-05 Donnelly Corporation Complete mirror-based global-positioning system (GPS) navigation solution
ES2308844T3 (es) 1998-07-15 2008-12-01 The Brigham And Women's Hospital, Inc. Vacuna de polisacaridos para infecciones estafilococidas.
NZ509986A (en) * 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US7167796B2 (en) 2000-03-09 2007-01-23 Donnelly Corporation Vehicle navigation system for use with a telematics system
US7370983B2 (en) 2000-03-02 2008-05-13 Donnelly Corporation Interior mirror assembly with display
US7581859B2 (en) 2005-09-14 2009-09-01 Donnelly Corp. Display device for exterior rearview mirror
US7255451B2 (en) 2002-09-20 2007-08-14 Donnelly Corporation Electro-optic mirror cell
ES2287266T3 (es) 2001-01-23 2007-12-16 Donnelly Corporation Sistema de iluminacion de vehiculos mejorado.
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2003094961A1 (en) 2002-05-09 2003-11-20 Massimo Porro Improved polysaccharide and glycoconjugate vaccines_____________
US7310177B2 (en) 2002-09-20 2007-12-18 Donnelly Corporation Electro-optic reflective element assembly
US8663656B2 (en) 2002-10-11 2014-03-04 Novartis Ag Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN103405761A (zh) 2003-10-02 2013-11-27 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
AU2005209303A1 (en) * 2004-01-29 2005-08-11 Biosynexus, Inc. Use of amino-oxy functional groups in the preparation of vaccines conjugates
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
DK1740217T3 (da) 2004-04-30 2011-09-26 Novartis Ag Meningokok-konjugat-vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
US8246993B2 (en) * 2004-06-10 2012-08-21 Cytogel Pharma, Llc Advantageous hydrogel composition
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
US20060013886A1 (en) * 2004-06-28 2006-01-19 Daqing Wu Injectable microspheres
US20060062779A1 (en) 2004-09-21 2006-03-23 The Brigham And Women's Hospital, Inc. Methods and compositions relating to mannuronic acid specific binding peptides
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
PL2097102T3 (pl) 2006-09-07 2012-10-31 Glaxosmithkline Biologicals Sa Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
PE20090212A1 (es) 2007-05-02 2009-03-30 Glaxosmithkline Biolog Sa Kit de vacuna para la inmunizacion primaria
GB0713880D0 (en) * 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US8017898B2 (en) 2007-08-17 2011-09-13 Magna Electronics Inc. Vehicular imaging system in an automatic headlamp control system
WO2009046268A1 (en) 2007-10-04 2009-04-09 Magna Electronics Combined rgb and ir imaging sensor
MX2010004271A (es) 2007-10-19 2010-05-03 Novartis Ag Formulaciones de vacuna meningococica.
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
SI2349520T1 (sl) 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
CN102300585A (zh) 2008-12-17 2011-12-28 诺华有限公司 包含血红蛋白受体的脑膜炎球菌疫苗
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
MX2011010735A (es) 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
EP2470204B1 (en) 2009-08-27 2015-12-16 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
JP2013504556A (ja) 2009-09-10 2013-02-07 ノバルティス アーゲー 気道疾患に対する組み合わせワクチン
MX373250B (es) 2009-09-30 2020-05-04 Glaxosmithkline Biologicals S A Star Conjugación de polisacáridos capsulares de tipo 5 y de tipo 8 de staphylococcus aureus.
WO2011039631A2 (en) 2009-09-30 2011-04-07 Novartis Ag Expression of meningococcal fhbp polypeptides
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
US9060965B2 (en) 2009-10-30 2015-06-23 Glaxosmithkline Biologicals Sa Purification of Staphylococcus aureus type 5 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP3090755A1 (en) 2010-05-21 2016-11-09 Cytogel Pharma, LLC Materials and methods for treatment of inflammation
EP2585106A1 (en) 2010-06-25 2013-05-01 Novartis AG Combinations of meningococcal factor h binding proteins
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
TR201811280T4 (tr) 2011-03-02 2018-08-27 Glaxosmithkline Biologicals Sa Düşük antijen ve/ veya adjuvan dozları olan karma aşılar.
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
EP3785730B1 (en) 2011-12-06 2024-04-24 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
EP2797624A1 (en) 2011-12-29 2014-11-05 Novartis AG Adjuvanted combinations of meningococcal factor h binding proteins
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
EP2872535A1 (en) 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CN105307684A (zh) 2012-10-02 2016-02-03 葛兰素史密丝克莱恩生物有限公司 非直链糖缀合物
KR20150065878A (ko) 2012-10-12 2015-06-15 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 백신에서 사용하기 위한 가교되지 않은 무세포 백일해 항원
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
RU2737638C2 (ru) * 2013-12-03 2020-12-01 Вирометикс Аг ПРОЛИН-БОГАТЫЕ ПЕПТИДЫ, ЗАЩИЩАЮЩИЕ ОТ S.pneumoniae
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
TWI850197B (zh) * 2017-06-23 2024-08-01 美國馬里蘭大學巴爾的摩分校 免疫原性組成物
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH396316A (de) * 1960-07-12 1965-07-31 Wander Ag Dr A Verfahren zur Herstellung von Impfstoffen
US3987164A (en) * 1970-10-20 1976-10-19 Yuzuru Homma Method for prevention of pseudomonas aeruginosa infections
US4185090A (en) * 1972-02-02 1980-01-22 Abbott Laboratories Chemically modified endotoxin immunizing agent
IL47412A0 (en) * 1974-06-04 1975-08-31 Wellcome Found Prostaglandin conjugates,their preparation and pharmaceutical compositions containing them
JPS51106714A (enExample) * 1975-03-12 1976-09-21 Tokyo Daigaku
JPS5296729A (en) * 1976-02-05 1977-08-13 Shionogi & Co Ltd Mixed vaccin for cyanomycosis
FR2460139A1 (fr) * 1979-06-29 1981-01-23 Pasteur Institut Fraction antigenique glycopeptidique vaccinante a tres grande immunogenicite isolee de cultures de germes pathogenes, procedes d'isolement de cette fraction et vaccins contenant ladite fraction
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
US4285936A (en) * 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine

Also Published As

Publication number Publication date
US4663160A (en) 1987-05-05
DE3478789D1 (en) 1989-08-03
EP0306607A1 (en) 1989-03-15
JPH0577657B2 (enExample) 1993-10-27
EP0118831A3 (en) 1986-12-10
JPS59175440A (ja) 1984-10-04
EP0118831B1 (en) 1989-06-28
EP0118831A2 (en) 1984-09-19

Similar Documents

Publication Publication Date Title
ATE44238T1 (de) Vakzine fuer gramnegative bakterien und verfahren zur herstellung derselben.
SE7708845L (sv) Framstellning av d(-)-3-hydroxismorsyra
ATE264326T1 (de) Verfahren zur herstellung von imidazochinolinaminen
ATE124458T1 (de) Verfahren zur herstellung von bis-homo-gamma- linolensäure.
DE69826851D1 (de) Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
DE69220746D1 (de) Verfahren zur Herstellung einer mehrfach ungesättigten Fettsäure des Omega 9 Typs
ATE109202T1 (de) Avirulenter vibrio cholerae und verfahren zu seiner herstellung.
DE69112716D1 (de) Verfahren zur biologischen Herstellung einer Hydroxyvitamin-D-Verbindung.
ATE30713T1 (de) Isolierung von enzymatisch erzeugten carbonsaeuren.
EP0090660A3 (en) Neisseria gonorrhoeae vaccine
DE68912236D1 (de) Verfahren zur Herstellung von hochgradig ungesättigten Fettsäuren.
DE3874565D1 (de) Verfahren zur herstellung von hydroxybiphenylen.
ATE127470T1 (de) Verfahren zur herstellung von phosphatidylcholinderivaten.
DE69531690D1 (de) Reinigungsverfahren für von bordetella produziertem nekrotoxin
KR840002855A (ko) Omt에스테르 유도체의 제조방법
DE69530959D1 (de) Verfahren zur Herstellung einer L-Aminosäure
DE3163814D1 (en) Homocitric acid oligoriboside derivatives, process for their manufacture and their use as preventives of dental caries
DE3877510D1 (de) Verfahren zur herstelllung von brenztraubensaeure.
DE68925951D1 (de) Chemisches Verfahren zur Herstellung des Antibiotikums L 17392 (Deglukoteicoplanin) und dessen Salze
DE3588014D1 (de) Verfahren zur herstellung bissilylierter 3-iodmethylcephalosporinderivaten.
SE8403929L (sv) Rekombinant-dna-molekyl, transformerade mikroorganismer och forfarande for framstellning av penicillin v-amidas
KR830007668A (ko) 6-아미노페니실란산 유도체의 제조방법
ATE21033T1 (de) Verfahren zur herstellung eines immunogens aus pasteurella multocida.
ATE23149T1 (de) Verfahren zur umkehrung der konfiguration optisch aktiver verbindungen und optisch aktive zwischenprodukte dieses verfahrens.
FI102973B (fi) Menetelmä 17-oksosteroidien valmistamiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee